Construction of Scientific Management Mode of "Adjuvant Drugs" Based on Evidence-Based Medicine
Department of Pharmacy, Shandong Provincial Third Hospital, Cheeloo College of Medicine, Shandong University, Jinan, Shandong 250031, 1Department of Medicine, Xintai People’s Hospital, Xintai, Shandong, 271200, China
Lei Zheng, Department of Pharmacy, Shandong Provincial Third Hospital, Cheeloo College of Medicine, Shandong University, Jinan, Shandong 250031, China, E-mail: firstname.lastname@example.org
This study aimed to standardize the clinical application of adjuvant drugs and control the unreason-able increase in drug costs. Management measures were formulated for adjuvant drug utilization by promoting the rational use of adjuvant drugs. The efficacy and economics of the same types of drugs were compared to provide a scientific reference for clinical drug selection. In 2018, the total cost of the use of adjuvant drugs decreased by 7.4117 million renminbi compared with that in 2015. In the first half of 2019, the proportion of revenue from adjuvant drugs decreased by 10.77 % from that in the same period in 2015. From 2015 to 2018, the per capita drug cost of adjuvant drugs gradually decreased and in 2018, this resulted in savings of 568.41 renminbi. Through administrative intervention, prescription review, information management and pharmaco-economic evaluation, a scientific management system of adjuvant drugs was established to standardize the use of adjuvant drugs and to reduce their cost. The scientific management of adjuvant drugs can avoid unnecessary drug expenses for patients and provide effective reference values for the rational use of adjuvant drugs in hospitals.